Abstract library

316 results for "CgA levels".
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#441 Tie-2 and Angiopoietin-2 Plasma Levels as New Diagnostic Markers for Patients with Neuroendocrine Tumors. Data from One Clinical Center
Introduction: Data concerning circulating levels of the angiogenic factors in patients with neuroendocrine tumors (NET) still remain insufficient.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Gabriela Melen-Mucha
#594 Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors
Introduction: Recent European investigations demonstrated that persistently elevated (> 50 pg/ml) plasma neurokinin A (NKA) levels are associated with poor short-term survival in patients with midgut neuroendocrine tumors (NETS).
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Eugene Woltering
#830 The Predictive Value of Gastrin Levels for the Diagnosis of Gastric Enterochromaffin-like Cells Hyperplasia, in Patients with Hashimoto’s Thyroiditis
Introduction: Gastrin and chromogranin A (CgA) levels have been tested for the diagnosis of enterochromaffin-like cell hyperplasia (ECLH), in patients with type 1 diabetes and autoimmune atrophic gastritis but there are no data for patients with Hashimoto's thyroiditis (HT).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Dimitrios Thomas
#1145 The Association Between Gastrin and Glucose Serum Concentration
Introduction: Gastrin is an early incretin candidate, since it is released by oral glucose and potentiates the glucose- induced insulin secretion. It has been shown that only in hypoglycemic or hyperglycemic conditions gastrin release is influenced by changes in blood glucose and insulin concentrations.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD Krystallenia Alexandraki
#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr Amit Tirosh
#1068 Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#1325 Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Franco Grimaldi
Authors: Grimaldi F, Motta C, Cipri C, Tonelli V, ...
Keywords: Tumor marker
#2213 Imaging Modality Depending on the Levels of Tumor Markers
Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: DOCTOR Julieta Iorio
Authors: Iorio J, Eleta M, Cuneo L, Polillo D, ...